Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy.
Gomez-Iturriaga A, Crook J, Casquero F, Carvajal C, Urresola A, Canteli B, Ezquerro A, Hortelano E, Cacicedo J, Espinosa JM, Perez F, Minguez P, Bilbao P. Gomez-Iturriaga A, et al. J Contemp Brachytherapy. 2014 Jun;6(2):154-60. doi: 10.5114/jcb.2014.43299. Epub 2014 Jun 9. J Contemp Brachytherapy. 2014. PMID: 25097555 Free PMC article.
Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
Gomez-Iturriaga A, Casquero F, Urresola A, Ezquerro A, Lopez JI, Espinosa JM, Minguez P, Llarena R, Irasarri A, Bilbao P, Crook J. Gomez-Iturriaga A, et al. Radiother Oncol. 2016 Apr;119(1):91-6. doi: 10.1016/j.radonc.2016.02.004. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900090 Clinical Trial.
Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J, Fernandez I, Del Hoyo O, Navarro A, Gomez-Iturriaga A, Pijoan JI, Martinez-Indart L, Escudero J, Gomez-Suarez J, de Zarate RO, Perez JF, Bilbao P, Rades D. Cacicedo J, et al. Clin Transl Oncol. 2017 Nov;19(11):1337-1349. doi: 10.1007/s12094-017-1674-6. Epub 2017 May 24. Clin Transl Oncol. 2017. PMID: 28540535
Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
Gomez-Iturriaga A, Casquero F, Pijoan JI, Crook J, Urresola A, Ezquerro A, Villeirs GM, Bossi A, Cacicedo J, Buchser D, Bilbao P. Gomez-Iturriaga A, et al. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1172-1178. doi: 10.1016/j.ijrobp.2018.04.039. Epub 2018 Apr 22. Int J Radiat Oncol Biol Phys. 2018. PMID: 29861199
Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D, Casquero F, Espinosa JM, Perez F, Minguez P, Martinez-Indart L, Suarez F, Gonzalez A, Cacicedo J, San Miguel I, Maleta A, Gomez-Caamaño A, Bilbao P, Gomez-Iturriaga A. Büchser D, et al. Radiother Oncol. 2019 Jun;135:13-18. doi: 10.1016/j.radonc.2019.02.018. Epub 2019 Mar 5. Radiother Oncol. 2019. PMID: 31015158
Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Gomez-Iturriaga A, Casquero Ocio F, Ost P, Fernandez I, Rodeño E, Llarena R, Garcia-Olaverri J, Ortiz de Zarate R, Cacicedo J, Ahtamon A, Bilbao P. Gomez-Iturriaga A, et al. Eur J Cancer Care (Engl). 2019 Sep;28(5):e13093. doi: 10.1111/ecc.13093. Epub 2019 May 21. Eur J Cancer Care (Engl). 2019. PMID: 31115124
67 results